ARS Pharmaceuticals (SPRY) Other Gross PP&E Adjustments: 2021-2025
Historic Other Gross PP&E Adjustments for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to -$1.7 million.
- ARS Pharmaceuticals' Other Gross PP&E Adjustments fell 117.64% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year decrease of 205.17%. This contributed to the annual value of -$1.4 million for FY2024, which is 18.31% down from last year.
- Per ARS Pharmaceuticals' latest filing, its Other Gross PP&E Adjustments stood at -$1.7 million for Q3 2025, which was up 17.75% from -$2.0 million recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' Other Gross PP&E Adjustments peaked at $70,000 during Q2 2024, and registered a low of -$5.6 million during Q3 2021.
- For the 3-year period, ARS Pharmaceuticals' Other Gross PP&E Adjustments averaged around -$731,000, with its median value being -$460,000 (2025).
- Per our database at Business Quant, ARS Pharmaceuticals' Other Gross PP&E Adjustments soared by 117.30% in 2024 and then tumbled by 3,014.29% in 2025.
- Over the past 5 years, ARS Pharmaceuticals' Other Gross PP&E Adjustments (Quarterly) stood at -$598,000 in 2021, then plummeted by 292.47% to -$2.3 million in 2022, then soared by 50.66% to -$1.2 million in 2023, then declined by 18.31% to -$1.4 million in 2024, then plummeted by 117.64% to -$1.7 million in 2025.
- Its Other Gross PP&E Adjustments was -$1.7 million in Q3 2025, compared to -$2.0 million in Q2 2025 and -$460,000 in Q1 2025.